TD Cowen Reaffirms “Buy” Rating for Twist Bioscience (NASDAQ:TWST)

Twist Bioscience (NASDAQ:TWST)‘s stock had its “buy” rating reaffirmed by TD Cowen in a note issued to investors on Tuesday,Benzinga reports. They currently have a $58.00 target price on the stock. TD Cowen’s target price suggests a potential upside of 23.72% from the company’s current price.

A number of other research firms also recently weighed in on TWST. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Finally, Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.00.

Twist Bioscience Stock Up 1.0 %

NASDAQ TWST traded up $0.48 during trading hours on Tuesday, hitting $46.88. The company’s stock had a trading volume of 246,691 shares, compared to its average volume of 949,587. Twist Bioscience has a twelve month low of $23.07 and a twelve month high of $60.90. The firm has a market capitalization of $2.78 billion, a P/E ratio of -13.02 and a beta of 1.78. The stock has a fifty day moving average of $43.78 and a 200 day moving average of $46.18.

Insider Buying and Selling

In related news, Director Robert Chess sold 3,600 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the transaction, the director now owns 21,641 shares in the company, valued at approximately $1,022,753.66. This represents a 14.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dennis Cho sold 659 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now directly owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock worth $4,391,151 over the last ninety days. Company insiders own 3.92% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of TWST. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience in the third quarter valued at $34,000. Signaturefd LLC raised its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. boosted its position in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience during the second quarter worth $61,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.